Master Protocol Clinical Trials for Evidence Generation
Ruixiao Lu
Sold by Rarewaves USA, OSWEGO, IL, U.S.A.
AbeBooks Seller since 10 June 2025
New - Soft cover
Condition: New
Ships within U.S.A.
Quantity: 1 available
Add to basketSold by Rarewaves USA, OSWEGO, IL, U.S.A.
AbeBooks Seller since 10 June 2025
Condition: New
Quantity: 1 available
Add to basketDrug development is at a crossroads. As personalized medicine and targeted therapies expand, traditional clinical trial models have become too slow, costly, and inefficient. To meet the urgent need for faster, reliable evidence generation and decision making, researchers and regulators alike have turned to innovative trial designs. Among these, master protocols stand out as a transformative approach, allowing multiple therapies, disease subtypes, or objectives to be studied under a single, integrated framework. Proven successful in oncology, COVID-19, and beyond, they improve efficiency, reduce participant exposure to ineffective treatments, and accelerate meaningful outcomes with patient centric approach, prompting regulatory guidance and global adoption.This book provides a multidisciplinary exploration of master protocol clinical trials, blending clinical, statistical, regulatory, operational, economic insights and patients perspectives. It examines both opportunities and challenges in design and implementation, and provides in-depth summary and discussion on real-world examples such as I-SPY, ROAR, and RECOVERY. A practical guide for researchers, statisticians, regulators, and industry professionals, it demonstrates how master protocols can reshape drug development and bring innovative therapies to patients faster.? Provides comprehensive, theoretical and practical aspects for master protocol trials? Includes most recent development in the master protocol clinical trials? Covers broad topics such as trial designs, governance oversight, software implementation, database and data pipeline, multi-regional trials, risk and benefit with operational solutions, economic considerations, regulatory perspectives, patient engagement and diversity? Deep dives into numerous real world case studies, their underlying thinking, challenges and success.? Includes global perspective in multi-regional clinical development.
Seller Inventory # LU-9781032544540
Drug development is at a crossroads. As personalized medicine and targeted therapies expand, traditional clinical trial models have become too slow, costly, and inefficient. To meet the urgent need for faster, reliable evidence generation and decision making, researchers and regulators alike have turned to innovative trial designs. Among these, master protocols stand out as a transformative approach, allowing multiple therapies, disease subtypes, or objectives to be studied under a single, integrated framework. Proven successful in oncology, COVID-19, and beyond, they improve efficiency, reduce participant exposure to ineffective treatments, and accelerate meaningful outcomes with patient centric approach, prompting regulatory guidance and global adoption.
This book provides a multidisciplinary exploration of master protocol clinical trials, blending clinical, statistical, regulatory, operational, economic insights and patients perspectives. It examines both opportunities and challenges in design and implementation, and provides in-depth summary and discussion on real-world examples such as I-SPY, ROAR, and RECOVERY. A practical guide for researchers, statisticians, regulators, and industry professionals, it demonstrates how master protocols can reshape drug development and bring innovative therapies to patients faster.
● Provides comprehensive, theoretical and practical aspects for master protocol trials
● Includes most recent development in the master protocol clinical trials
● Covers broad topics such as trial designs, governance oversight, software implementation, database and data pipeline, multi-regional trials, risk and benefit with operational solutions, economic considerations, regulatory perspectives, patient engagement and diversity
● Deep dives into numerous real world case studies, their underlying thinking, challenges and success.
● Includes global perspective in multi-regional clinical development
Ruixiao Lu
Dr. Ruixiao Lu is a recognized leader in the biotech and biopharma industry, currently serving as Vice President, Head of Biostatistics & Statistical Programming at Alumis Inc. She has held senior leadership roles at various companies, where she led end-to-end data analytical teams supporting product development, medical affairs, and strategic initiatives. An elected Fellow of American Statistical Association (ASA), she is dedicated to advancing statistics and data science through professional organizations such as ASA, BBSW, and DahShu, as elected Board Director of ASA (2026- 2028), BBSW President and Board Member (2024- 2026), and co-founder of DahShu (2015- ), and is deeply engaged in cross-disciplinary collaborations, with a proven record of success to promote scientific excellence and improve public health outcomes, such as the 2023 FDA-AACR-ASA Oncology Overall Survival Workshop.
Jingjing Ye
Dr. Jingjing Ye is executive director and global head of Product Management and Data Insights (PMDI) in Global Statistics and Data Sciences (GSDS) at BeOne Medicines, leading a diverse global team in R&D for their data and analytical initiatives. With over 18 years of experience in the pharmaceutical industry and US FDA, she focuses on cancer drug discovery and development, covering the full spectrum of patients' treatment journeys. Her research interests include innovative trial designs for small populations. As a Fellow of the American Statistical Association, she is actively engaged in advancing statistics and data science in pharmaceutical drug development through professional organizations. She is also an elected ICSA board of directors (2026-2028).
Chengxing (Cindy) Lu
Dr. Chengxing (Cindy) Lu is a Senior Director of Oncology Biometrics in AstraZeneca, where she leads a team of statisticians dedicated to early-phase oncology development. Throughout her extensive career in drug discovery and development, her work has spanned the full spectrum of the field, encompassing early and late-stage clinical development as well as post-marketing, medical affairs, reimbursement and commercial strategies. Cindy is deeply committed to driving innovation and enhancing efficiency through multidisciplinary collaborations. She is actively engaged with the professional community through organizations such as the American Statistical Association (ASA), DahShu, DIA, and the International Society of Biopharmaceutical Statistics (ISBS), where she advocates for advanced statistical methodologies and promotes best practices that integrate multidisciplinary perspectives for real-world applications in drug development.
William (Bill) Wang
Dr. William (Bill) Wang is Executive Director in the Department of Biostatistics and Research Decision Sciences (BARDS) at Merck Research Laboratories (MRL). During 25+ years of experience in MRL, he has contributed extensively to clinical trial design, analysis/reporting, and regulatory filings across multiple therapeutic areas. Bill has led the design and build-up of MRL’s global biometrics operations in Asia-Pacific, and has spearheaded the establishment of the Clinical Safety Statistics group. Bill is an elected ASA fellow and has served as a core member in the ICH E17 expert working group and implementation working group.
"About this title" may belong to another edition of this title.
If you are a consumer you can cancel the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.
INFORMATION REGARDING THE RIGHT OF CANCELLATION
Statutory Right to cancel
You have the right to cancel this contract within 14 days for any reason.
The cancellation period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the the last good or the last lot or piece.
To exercise the right to cancel, you must inform us, Rarewaves USA, 10100 W Sample Rd, Ste 101, 33065, Coral Springs, Florida, U.S.A., of your decision to cancel this contract by a clear statement (e.g. a letter sent by post, fax or e-mail). You may use the attached model cancellation form, but it is not obligatory. You can also electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". If you use this option, we will communicate to you an acknowledgement of receipt of such a cancellation on a durable medium (e.g. by e-mail) without delay.
To meet the cancellation deadline, it is sufficient for you to send your communication concerning your exercise of the right to cancel before the cancellation period has expired.
Effects of cancellation
If you cancel this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).
We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.
We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to cancel with contract.
We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.
We may withhold reimbursement until we have received the goods back or you have supplied evidence of having sent back the goods, whichever is the earliest.
You shall send back the goods or hand them over to us or Rarewaves USA, 10100 W Sample Rd, Ste 101, 33065, Coral Springs, Florida, U.S.A., without undue delay and in any event not later than 14 days from the day on which you communicate your cancellation from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.
Exceptions to the right of cancellation
The right of cancellation does not apply to:
Model withdrawal form
(complete and return this form only if you wish to withdraw from the contract)
To: (Rarewaves USA, 10100 W Sample Rd, Ste 101, 33065, Coral Springs, Florida, U.S.A.)
I/We (*) hereby give notice that I/We (*) withdraw from my/our (*) contract of sale of the following goods (*)/for the provision of the following goods (*)/for the provision of the following service (*),
Ordered on (*)/received on (*)
Name of consumer(s)
Address of consumer(s)
Signature of consumer(s) (only if this form is notified on paper)
Date
* Delete as appropriate.
Please note that we do not offer Priority shipping to any country.
We currently do not ship to the below countries:
Afghanistan
Bhutan
Brazil
Brunei Darussalam
Channel Islands
Chile
Israel
Lao
Mexico
Russian Federation
Saudi Arabia
South Africa
Yemen
Please do not attempt to place orders with any of these countries as a ship to address - they will be cancelled.
| Order quantity | 6 to 9 business days | 6 to 9 business days |
|---|---|---|
| First item | £ 0.00 | £ 0.00 |
Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.